Remarkably, arsenic trioxide, an FDA-approved drug for acute promyelocytic leukemia, has also been reported to act at the level of GLI by not only disturbing the stability and ciliary translocation of GLI2 but also directly binding to GLI1 (61, 175). This evidence concerns the gene GLI1 and acute promyelocytic leukemia.